Drawing for PREVECEUTICAL

USPTO serial 86645468

PREVECEUTICAL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
COHEN, ROBERT ANDREW
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with PREVECEUTICAL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Ben Natter

BEN NATTER NATTER & NATTER501 Fifth AvenueNew York, NY 10017UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment and prevention of Addison's Disease, Agammaglobulinemia, Alopecia Areata, Amyloidosis, Ankylosing Spondylitis, Anti-Gbm/Anti-Tbm Nephritis, Antiphospholipid Syndrome (Aps), Autoimmune Hepatitis, Autoimmune Inner Ear Disease (Aied), Axonal and Neuronal Neuropathy (Aman), Arthritis, Baló's Concentric Sclerosis (Bcs), Behcet's Disease, Bullous Pemphigoid, Cancer, Castleman Disease (Cd), Celiac Disease, Chagas Disease, Chronic Inflammatory Demyelinating Polyneuropathy (Cidp), Chronic Recurrent Multifocal Osteomyelitis (Crmo), Churg-Strauss, Cicatricial Pemphigoid/Benign Mucosal Pemphigoid, Cogan's Syndrome Cold Agglutinin Disease, Congenital Heart Block, Coxsackie Myocarditis, Crest Syndrome, Crohn's Disease, Dermatitis Herpetiformis, Dermatomyositis, Devic's Disease (Neuromyelitis Optica), Diabetes, Discoid Lupus, Dressler's Syndrome, Endometriosis, Essential Mixed Cryoglobulinemia, Eosinophilic Esophagitis (Eoe), Evans Syndrome, Fibromyalgia, Fibrosing Alveolitis, Giant Cell Arteritis (Temporal Arteritis), Giant Cell Myocarditis, Glomerulonephritis, Goodpasture's Syndrome, Granulomatosis With Polyangiitis (Gpa), Graves' Disease, Guillain-Barre Syndrome, Hashimoto's Thyroiditis, Hemolytic Anemia, Henoch-Schonlein Purpura (Hsp), Herpes Gestationis Or Pemphigoid Gestationis (Pg), Hypogammalglobulinemia, Immune Thrombocytopenic Purpura (Itp), Iga Nephropathy, Inclusion Body Myositis (Ibm), Interstitial Cystitis (Ic), Juvenile Arthritis, Juvenile Diabetes (Type 1 Diabetes), Juvenile Myositis (Jm), Kawasaki Disease, Lambert-Eaton Syndrome, Leukocytoclastic Vasculitis, Lichen Planus, Lichen Sclerosus, Ligneous Conjunctivitis, Linear Iga Disease (Lad), Lupus, Lyme Disease, Meniere's Disease, Microscopic Polyangiitis (Mpa), Mixed Connective Tissue Disease (Mctd), Mooren's Ulcer, Mucha-Habermann Disease, Multiple Sclerosis (Ms), Myasthenia Gravis, Myositis, Narcolepsy, Neuromyelitis Optica, Neutropenia, Ocular Cicatricial Pemphigoid, Optic Neuritis, Palindromic Rheumatism (Pr), Pandas (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcus), Paraneoplastic Cerebellar Degeneration (Pcd), Paroxysmal Nocturnal Hemoglobinuria (Pnh), Parry Romberg Syndrome, Parsonnage-Turner Syndrome, Pars Planitis, Pemphigus, Pernicious Anemia (Pa), Peripheral Neuropathy, Perivenous Encephalomyelitis, Poems Syndrome, Polyarteritis Nodosa, Polymyalgia Rheumatic, Polymyositis, Postmyocardial Infarction Syndrome, Postpericardiotomy Syndrome, Progesterone Dermatitis, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Psoriatic Arthritis, Idiopathic Pulmonary Fibrosis, Pyoderma Gangrenosum, Pure Red Cell Aplasia (Prca), Raynaud's Phenomenon, Reactive Arthritis, Reflex Sympathetic Dystrophy, Reiter's Syndrome, Relapsing Polychondritis, Restless Legs Syndrome (Rls), Retroperitoneal Fibrosis, Rheumatic Fever, Rheumatoid Arthritis (Ra), Sarcoidosis, Schmidt Syndrome, Scleritis, Scleroderma, Sjogren's Syndrome, Sperm and Testicular Autoimmunity, Stiff Person Syndrome (Sps), Subacute Bacterial Endocarditis (Sbe), Susac's Syndrome, Sympathetic Ophthalmia (So), Takayasu's Arteritis, Temporal Arteritis/Giant Cell Arteritis, Thrombocytopenic Purpura (Ttp), Tolosa-Hunt Syndrome (Ths), Transverse Myelitis, Type 1 Diabetes, Ulcerative Colitis (Uc), Undifferentiated Connective Tissue Disease (Uctd), Uveitis, Vasculitis, Vitiligo and Wegener's GranulomatosisACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Feb 27, 2017MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 27, 2017ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 27, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 25, 2016EX1GSOU EXTENSION 1 GRANTED—
Jul 25, 2016EXT1SOU EXTENSION 1 FILED—
Jul 25, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 30, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 30, 2016TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 24, 2016ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jan 26, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 1, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 1, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 11, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 27, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 26, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 23, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 23, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 16, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 11, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 10, 2015DOCKASSIGNED TO EXAMINER—
Jul 1, 2015AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Jun 24, 2015ALIEASSIGNED TO LIE—
Jun 16, 2015PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Jun 4, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 2, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance